Atopic Dermatitis - The Dermatology Digest

TDD Expert Reaction: U.S. FDA Approves Roflumilast Cream 0.05% for AD in Kids Aged 2 to 5 Featuring Dr. Lawrence Eichenfield

October 8, 2025

NEA to Hold Capitol Hill Policy Summit to Reform Step Therapy, Reduce Prior Authorization Burdens

October 8, 2025

U.S. FDA Approves Roflumilast Cream 0.05% for AD in Kids Aged 2 to 5

October 6, 2025

Targeting IL-22 in AD: A Q&A About LEO Pharma’s Temtokibart With Michael Ardern-Jones

October 1, 2025

TDD News Brief: Nevisense Can Detect Skin Barrier Dysfunction in AD

September 26, 2025

AD Pipeline Watch: Bambusa’s BBT001 Advances to Patient Dosing

September 25, 2025

Advertisement

Advertisement

Latest Issue

Latest Supplements

Upcoming Conferences

Advertisement

Advertisement

Digital Edition Archive